首页> Nature communications> Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy.

Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy.

导出 OA

翻译打印收藏纠错

第一作者： Zhangyi,Luo

第一单位： Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA.;UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.

作者： Zhangyi,Luo ^[1] ; Yixian,Huang ^[1] ; Neelu,Batra ^[2] ; Yuang,Chen ^[1] ; Haozhe,Huang ^[1] ; Yifei,Wang ^[1] ; Ziqian,Zhang ^[1] ; Shichen,Li ^[1] ; Chien-Yu,Chen ^[1] ; Zehua,Wang ^[1] ; Jingjing,Sun ^[1] ; Qiming Jane,Wang ^[3] ; Da,Yang ^[1] ; Binfeng,Lu ^[4] ; James F,Conway ^[5] ; Lu-Yuan,Li ^[6] ; Ai-Ming,Yu ^[2] ; Song,Li ^[7]

作者单位： Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA.;UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA. ^[1] Department of Biochemistry and Molecular Medicine, University of California, Davis, School of Medicine, Sacramento, CA, USA. ^[2] Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. ^[3] Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA. ^[4] Department of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. ^[5] UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.;State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin, China. ^[6] Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA. sol4@pitt.edu.;UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA. sol4@pitt.edu. ^[7]